Evidence map›Paper›PMID 38138949›Full record

ArticleJournal of personalized medicine2023

Association between Conflicts of Interest Disclosure and Quality of Clinical Practice Guidelines in Japan: A Meta-Epidemiological Study.

Norio Yamamoto, Akihiko Ozaki, Shunsuke Taito, Takashi Ariie, Hidehiro Someko, Hiroaki Saito, Tetsuya Tanimoto, Yuki Kataoka

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Norio YamamotoDepartment of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.ORCID 0000-0002-7902-9994
Akihiko OzakiMedical Governance Research Institute, Tokyo 113-8510, Japan.ORCID 0000-0003-4415-9657
Shunsuke TaitoScientific Research WorkS Peer Support Group (SRWS-PSG), Osaka 541-0043, Japan.ORCID 0000-0003-1218-4225
Takashi AriieScientific Research WorkS Peer Support Group (SRWS-PSG), Osaka 541-0043, Japan.
Hidehiro SomekoScientific Research WorkS Peer Support Group (SRWS-PSG), Osaka 541-0043, Japan.ORCID 0000-0002-7195-2055
Hiroaki SaitoDepartment of Internal Medicine, Soma Central Hospital, Fukushima 975-0033, Japan.ORCID 0000-0002-0824-454X
Tetsuya TanimotoDepartment of Internal Medicine, Navitas Clinic, Tokyo 160-0022, Japan.
Yuki KataokaScientific Research WorkS Peer Support Group (SRWS-PSG), Osaka 541-0043, Japan.ORCID 0000-0001-7982-5213

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate disclosure of financial conflicts of interest (COI) among clinical practice guideline (CPG) developers is critical to ensure the quality of CPGs. However, there is limited evidence on the impact of underreporting COIs on the quality of CPGs. This study aimed to examine the proportion of underreported COI disclosures in the development of Japanese CPGs and to estimate the association between underreported COIs and CPG quality using the Appraisal of Guidelines for Research & Evaluation (AGREE) II. Twenty-three Japanese CPGs published in 2019 and their 1114 developers were included in the study. The results show that underreporting of COIs occurred in 52% of the included CPGs and 8% of all CPG developers. Underreporting COI disclosures was negatively associated with low-quality CPG (Odds ratio [OR], 0.57; 95% confidence interval [CI]: 0.11, 3.04). On the other hand, CPGs that had more than 13% of CPG developers with voting rights on recommendation decisions and underreporting of COI disclosures were positively associated with low quality (OR, 1.78; 95% CI: 0.25, 12.45). For individual CPG developers with voting rights for recommendation decisions, the presence of a COI was positively associated with low quality (OR, 1.11; 95% CI: 0.71, 1.75). This study demonstrates that the involvement and underreporting of COIs did not seriously distort the CPG development process. However, the COI-related factors of CPG developers with voting rights for recommendation decisions may be associated with low CPG quality.

Indexed as

AGREE IIclinical guidelinesconflicts of interestfundingguideline committeeguideline development processJapan

Identifiers

PMID38138949
PMCPMC10744963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.